ライフサイエンスコーパス: coronary artery bypass grafting

1 4 underwent cardiac stenting and 8 underwent coronary artery bypass grafting).

2 should be considered more frequently during coronary artery bypass grafting.

3 nosis (AS) who underwent AVR with or without coronary artery bypass grafting.

4 e atrial fibrillation (PoAF) is common after coronary artery bypass grafting.

5 native coronary artery disease 1 year after coronary artery bypass grafting.

6 rel or aspirin plus placebo for 1 year after coronary artery bypass grafting.

7 ary intervention, and 2832 (10.7%) underwent coronary artery bypass grafting.

8 y high (50%), and 6 (13%) required emergency coronary artery bypass grafting.

9 , 57,961 patients underwent primary isolated coronary artery bypass grafting.

10 clude percutaneous coronary intervention and coronary artery bypass grafting.

11 with PCI), and only 3% of patients underwent coronary artery bypass grafting.

12 (>/=50%, 40%-49%, and <40%) and concomitant coronary artery bypass grafting.

13 of 2 arterial grafts in patients undergoing coronary artery bypass grafting.

14 -term survival prediction model for isolated coronary artery bypass grafting.

15 es were performed for patients with isolated coronary artery bypass grafting.

16 ed cohort of 10 000 patients undergoing redo coronary artery bypass grafting.

17 often used as the second arterial graft for coronary artery bypass grafting.

18 this contributes to clinical outcomes after coronary artery bypass grafting.

19 completely endoscopic robotic double vessel coronary artery bypass grafting.

20 o speed secondary prevention adherence after coronary artery bypass grafting.

21 ions, contemporary practice, and outcomes of coronary artery bypass grafting.

22 years old and those who undergo concomitant coronary artery bypass grafting.

23 improve short- and long-term outcomes after coronary artery bypass grafting.

24 ion, percutaneous coronary intervention, and coronary artery bypass grafting.

25 and improved survival in patients undergoing coronary artery bypass grafting.

26 scending (LAD) artery in patients undergoing coronary artery bypass grafting.

27 m were obtained from 306 patients undergoing coronary artery bypass grafting.

28 rone that was similar to patients undergoing coronary artery bypass grafting.

29 .0% of patients and were most frequent after coronary artery bypass grafting.

30 ated revascularization procedure (PCI 25.8%, coronary artery bypass grafting 1.7%).

31 eripheral arterial disease; and who received coronary artery bypass grafting (11.6% versus 21.2%; P<0

32 cept for fewer revascularization procedures (coronary artery bypass grafting: 12% versus 22%; P=0.03)

33 Concomitant procedures included coronary artery bypass grafting (13%), mitral valve repa

34 d the rates of major bleeding not related to coronary-artery bypass grafting (2.1% vs. 0.6%, P<0.001)

35 cardiac surgery before dissection, including coronary artery bypass grafting (34%), aortic or mitral

36 ronary intervention 5 percentage points, and coronary artery bypass grafting 4 percentage points.

37 o underwent coronary revascularization (6178 coronary artery bypass grafting, 5011 bare metal stents,

38 rcutaneous coronary intervention: 28 011 and coronary artery bypass grafting: 6277).

39 itial conservative management (31 of 87) and coronary artery bypass grafting (7 of 87) were associate

40 ne surgery (9.8%), herniorrhaphy (7.4%), and coronary artery bypass grafting (7.0%).

41 nary intervention (1.2 versus 3.2 hours) and coronary artery bypass grafting (7.9 versus 55.9 hours).

42 cularization of dysfunctional myocardium (79 coronary artery bypass grafting, 7 percutaneous coronary

43 At 12 to 18 months post-coronary artery bypass grafting, 782 of 1828 (42.8%) pat

44 vated troponin levels between studies, prior coronary artery bypass grafting, a left ventricular ejec

45 scharged after 10 major surgical procedures (coronary artery bypass grafting, abdominal aortic aneury

46 on adjusted OR: 0.74; 95% CI: 0.73 to 0.75) (coronary artery bypass grafting adjusted OR: 0.61; 95% C

47 cic Surgeons records; 162 572 (61%) isolated coronary artery bypass grafting admissions constituted t

48 no clear guidelines on the use of the RA in coronary artery bypass grafting after its catheterizatio

49 procedures (stress imaging, angiography, or coronary artery bypass grafting) after the index PCI wer

50 nt within 30 days was 10.2% for conventional coronary artery bypass grafting and 10.7% for OPCAB.

51 ber 2008, 13,926 patients underwent isolated coronary artery bypass grafting and 3248 patients had at

52 Sixty-seven patients completed follow-up (33 coronary artery bypass grafting and 34 percutaneous coro

53 needed to risk stratify patients undergoing coronary artery bypass grafting and identify candidates

54 Both conventional coronary artery bypass grafting and OPCAB are safe proce

55 Two cohorts of patients who underwent coronary artery bypass grafting and received perioperati

56 In-hospital coronary artery bypass grafting and renal insufficiency

57 cribes 20-year results of RA grafts used for coronary artery bypass grafting and the effects of RA re

58 Of 10 633 adults who underwent coronary artery bypass grafting and valve surgery betwee

59 fibrillation (AF) in patients who underwent coronary artery bypass grafting and were treated with pe

60 Patients having coronary artery bypass grafting and/or cardiac valve rep

61 lete LV diastolic function assessment before coronary artery bypass grafting and/or valve surgery bet

62 mes in 2,241 consecutive patients undergoing coronary artery bypass grafting and/or valve surgery fro

63 ly for aortic-valve replacement but fell for coronary-artery bypass grafting and carotid endarterecto

64 use were percutaneous coronary intervention, coronary artery bypass grafting, and heart transplant ca

65 primary percutaneous coronary intervention, coronary artery bypass grafting, and medical therapy, re

66 l artery (RA) is a commonly used conduit for coronary artery bypass grafting, and recent studies have

67 jury in percutaneous coronary interventions, coronary artery bypass grafting, and reperfused acute my

68 ubgroup analysis of patients undergoing only coronary artery bypass grafting, and results were simila

69 impact on the function of RA grafts used in coronary artery bypass grafting, and there is now compre

70 atinine clearance <60 mL/min, treatment with coronary artery bypass grafting, anemia, and diabetes me

71 These findings may help guide post-coronary artery bypass grafting antiplatelet therapy.

72 beneficiaries aged 65 to 99 years undergoing coronary artery bypass grafting, aortic valve repair, or

73 sion of native coronary artery disease after coronary artery bypass grafting are unknown.

74 underwent aortic valve replacement (AVR) and coronary artery bypass grafting (AS+CABG) with those of

75 bare metal stents, 19% with DES, and 6% with coronary artery bypass grafting at 1 year.

76 s should be maximized in patients undergoing coronary artery bypass grafting because they have excell

77 ified in the setting of isolated reoperative coronary artery bypass grafting, because it aids in appr

78 re and coronary artery disease often undergo coronary artery bypass grafting, but assessment of the r

79 tion, in-hospital mortality was higher after coronary artery bypass grafting, but long-term survival

80 uch that patients with low CFR who underwent coronary artery bypass grafting, but not percutaneous co

81 lectomy (189229 patients at 1876 hospitals), coronary artery bypass grafting (CABG) (218940 patients

82 after the procedure between on- and off-pump coronary artery bypass grafting (CABG) (n = 6; low SOE),

83 ery disease were randomly assigned to either coronary artery bypass grafting (CABG) (n = 97) or percu

84 injury (AKI) is a common complication after coronary artery bypass grafting (CABG) and is associated

85 n with percutaneous coronary intervention or coronary artery bypass grafting (CABG) and its long-term

86 o address the most recent evidence bases for coronary artery bypass grafting (CABG) and stenting in p

87 re, and coronary artery disease suitable for coronary artery bypass grafting (CABG) are at higher ris

88 ved ejection fraction in patients undergoing coronary artery bypass grafting (CABG) are limited and i

89 The long-term outcomes of off-pump coronary artery bypass grafting (CABG) are the subject o

90 tter conduits than saphenous vein grafts for coronary artery bypass grafting (CABG) based on experien

91 nd MV replacement and repair with or without coronary artery bypass grafting (CABG) between 2007 and

92 coronary syndromes (ACS) undergoing isolated coronary artery bypass grafting (CABG) compared with asp

93 unction who derive the greatest benefit from coronary artery bypass grafting (CABG) compared with med

94 study aimed to assess if clampless off-pump coronary artery bypass grafting (CABG) decreases risk-ad

95 telet therapy (DAPT) in patients who undergo coronary artery bypass grafting (CABG) following acute c

96 andomized clinical trials support the use of coronary artery bypass grafting (CABG) for patients with

97 review is to examine the appropriateness of coronary artery bypass grafting (CABG) for the patient w

98 h left main coronary artery (LMCA) stenosis, coronary artery bypass grafting (CABG) has been the stan

99 Clinical trials of off-pump coronary artery bypass grafting (CABG) have largely excl

100 eft anterior descending (LAD) at reoperative coronary artery bypass grafting (CABG) improves patient

101 Whether mitral valve repair during coronary artery bypass grafting (CABG) improves survival

102 n the need for repeat revascularization with coronary artery bypass grafting (CABG) in comparison to

103 The role of mitral valve repair (MVR) during coronary artery bypass grafting (CABG) in patients with

104 We hypothesized that outcomes after coronary artery bypass grafting (CABG) in the United Sta

105 mited data regarding long-term results after coronary artery bypass grafting (CABG) in young adults.

106 Acute kidney injury (AKI) after coronary artery bypass grafting (CABG) is common and inc

107 enosis of saphenous vein grafts (SVGs) after coronary artery bypass grafting (CABG) is common and oft

108 bare metal stent eras have demonstrated that coronary artery bypass grafting (CABG) is cost-effective

109 Coronary artery bypass grafting (CABG) is the standard t

110 ir perioperative role in patients undergoing coronary artery bypass grafting (CABG) is unclear.

111 (ASA) has been shown to reduce postoperative coronary artery bypass grafting (CABG) mortality and isc

112 Patients undergoing coronary artery bypass grafting (CABG) must often see mu

113 unclear whether revascularization by either coronary artery bypass grafting (CABG) or percutaneous c

114 itial coronary revascularization with either coronary artery bypass grafting (CABG) or percutaneous c

115 It is unknown if coronary artery bypass grafting (CABG) or percutaneous c

116 Today's coronary artery bypass grafting (CABG) population appear

117 d data on outcomes of patients with previous coronary artery bypass grafting (CABG) presenting with S

118 icated in stroke risk at the time of on-pump coronary artery bypass grafting (CABG) procedures.

119 Coronary artery bypass grafting (CABG) remains the stand

120 Current guidelines suggest that coronary artery bypass grafting (CABG) should be the pre

121 Readmissions are common after coronary artery bypass grafting (CABG) surgery and accou

122 omized trial data support the superiority of coronary artery bypass grafting (CABG) surgery over perc

123 ete revascularization in patients undergoing coronary artery bypass grafting (CABG) surgery.

124 al, 33 patients who were undergoing off-pump coronary artery bypass grafting (CABG) were randomly ass

125 ailure) trial compared a strategy of routine coronary artery bypass grafting (CABG) with guideline-ba

126 th from randomized trials that have compared coronary artery bypass grafting (CABG) with percutaneous

127 fined as percutaneous coronary intervention, coronary artery bypass grafting (CABG), and noncardiac s

128 acticality and appropriateness of FFR-guided coronary artery bypass grafting (CABG), as compared with

129 compared the results of on-pump and off-pump coronary artery bypass grafting (CABG), but little is kn

130 percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), on long-term out

131 cular (LV) biopsies from patients undergoing coronary artery bypass grafting (CABG), only the activat

132 t alone, percutaneous coronary intervention, coronary artery bypass grafting (CABG), or CABG plus mit

133 inical trials comparing a strategy of prompt coronary artery bypass grafting (CABG), percutaneous cor

134 In coronary artery bypass grafting (CABG), the combined use

135 ent literature on standardization of care in coronary artery bypass grafting (CABG), with particular

136 intervention (PCI)-related MI (type 4a) and coronary artery bypass grafting (CABG)-related MI (type

137 s may present an alternative to conventional coronary artery bypass grafting (CABG).

138 levation acute coronary syndromes undergoing coronary artery bypass grafting (CABG).

139 nt graft atherosclerosis and occlusion after coronary artery bypass grafting (CABG).

140 eart failure of ischemic etiology undergoing coronary artery bypass grafting (CABG).

141 (AAA) repair, esophageal resection (ER), and coronary artery bypass grafting (CABG).

142 matched nondiabetic (ND) patients undergoing coronary artery bypass grafting (CABG).

143 f prasugrel or clopidogrel withdrawal before coronary artery bypass grafting (CABG).

144 kly been adopted as the standard-of-care for coronary artery bypass grafting (CABG).

145 nd with a higher risk of complications after coronary artery bypass grafting (CABG).

146 an increased risk of adverse outcomes after coronary artery bypass grafting (CABG).

147 predict cardiovascular events or death after coronary artery bypass grafting (CABG).

148 cutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG).

149 percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).

150 percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG); a small percenta

151 afts intraoperatively in patients undergoing coronary artery bypass grafting (CABG); however, studies

152 inically significant bleeding not related to coronary artery bypass grafting (CABG; major, minor, or

153 The survival benefit of a strategy of coronary-artery bypass grafting (CABG) added to guidelin

154 In a trial comparing coronary-artery bypass grafting (CABG) alone with CABG p

155 he benefits of adding mitral-valve repair to coronary-artery bypass grafting (CABG) are uncertain.

156 heart failure, or pneumonia or who underwent coronary-artery bypass grafting (CABG) between 2003 and

157 ation strategies for patients with diabetes, coronary-artery bypass grafting (CABG) has had a better

158 Coronary-artery bypass grafting (CABG) has traditionally

159 The role of coronary-artery bypass grafting (CABG) in the treatment

160 ral internal thoracic (mammary) arteries for coronary-artery bypass grafting (CABG) may improve long-

161 ring dialysis between patients who underwent coronary-artery bypass grafting (CABG) performed with a

162 Coronary-artery bypass grafting (CABG) surgery may be pe

163 s have shown lower long-term mortality after coronary-artery bypass grafting (CABG) than after percut

164 ase and left ventricular dysfunction in whom coronary-artery bypass grafting (CABG) will provide a su

165 he relative benefits and risks of performing coronary-artery bypass grafting (CABG) with a beating-he

166 The benefits of coronary-artery bypass grafting (CABG) without cardiopul

167 death or major bleeding not associated with coronary-artery bypass grafting (CABG), and the principa

168 ts undergoing multivessel revascularization, coronary-artery bypass grafting (CABG), as compared with

169 episodes, whether related or not related to coronary-artery bypass grafting (CABG), through day 7 wa

170 percutaneous coronary intervention (PCI) and coronary-artery bypass grafting (CABG).

171 nary artery disease are usually treated with coronary-artery bypass grafting (CABG).

172 ries for 'Angina', 'Myocardial Infarction', 'Coronary Artery Bypass Grafting' (CABG), 'percutaneous t

173 nts present with clinical features that make coronary artery bypass grafting clinically unattractive.

174 ld have on previously cannulated RAs used as coronary artery bypass grafting conduits.

175 pressure, history of myocardial infarction, coronary artery bypass grafting, congestive heart failur

176 of CAD included prior myocardial infarction, coronary artery bypass grafting, congestive heart failur

177 e., no percutaneous coronary intervention or coronary artery bypass grafting during the index hospita

178 CABG from the European Multicenter Study on Coronary Artery Bypass Grafting (E-CABG) registry betwee

179 lve replacement and aortic valve replacement+coronary artery bypass grafting, extensive updating usin

180 A total of 508 patients who underwent coronary artery bypass grafting for cardiogenic shock co

181 ceived percutaneous coronary intervention or coronary artery bypass grafting for treatment of their A

182 In patients undergoing coronary artery bypass grafting, genetic variation in GR

183 dence interval, 0.70-0.79) and lowest in the coronary artery bypass grafting group (24.2%; adjusted h

184 ronary intervention and 51% of patients with coronary artery bypass grafting had undergone testing by

185 of these secondary prevention measures after coronary artery bypass grafting has been inconsistent.

186 ndomized controlled trial comparing HCR with coronary artery bypass grafting has recently emerged in

187 phy, percutaneous coronary intervention, and coronary artery bypass grafting) has expanded, yet natio

188 ternal mammary artery (BIMA) conduits during coronary artery bypass grafting have better long-term su

189 Nearly 50% of patients undergoing coronary artery bypass grafting have diabetes.

190 0.64; 95% confidence interval, 0.60-0.69) or coronary artery bypass grafting (hazard ratio, 0.53; 95%

191 inpatient surgery among patients undergoing coronary artery bypass grafting, hip replacement, back s

192 cardial infarction, immunosuppression, prior coronary artery bypass grafting, implanted pacemaker, lo

193 d national Medicare beneficiaries undergoing coronary artery bypass grafting in 2008 to 2010 (N = 255

194 ns about competitive flow and the benefit of coronary artery bypass grafting in intermediate LAD sten

195 ial infarction is an indication for emergent coronary artery bypass grafting in patients not amenable

196 antly higher risk of mortality and emergency coronary artery bypass grafting in patients treated by n

197 Emergency coronary artery bypass grafting in patients with acute m

198 ader spectrum of patients who are undergoing coronary artery bypass grafting in routine practice.

199 n, and percutaneous coronary intervention or coronary artery bypass grafting in the preceding 12 mont

200 previous cerebrovascular event, in-hospital coronary artery bypass grafting, in-hospital bleeding, a

201 percutaneous coronary intervention, and 298 coronary artery bypass grafting (increasing the proporti

202 Although coronary artery bypass grafting is generally preferred i

203 of a third arterial conduit in patients with coronary artery bypass grafting is not associated with h

204 ere negative baseline troponin values, prior coronary artery bypass grafting, lower baseline hemoglob

205 -main disease who underwent primary isolated coronary artery bypass grafting (MAG, n = 5580; LITA+SVG

206 Minimally invasive coronary artery bypass grafting (MICS CABG) consists of

207 Minimally invasive coronary artery bypass grafting (MICS CABG) is a novel c

208 ncluded age, sex, race, Deyo-Charlson index, coronary artery bypass grafting, myocardial infarction,

209 ies undergoing colectomy, lung resection, or coronary artery bypass grafting (n = 1,033,255) to creat

210 onary intervention (PCI; n=11 766, 60.8%) or coronary artery bypass grafting (n=3515, 18.2%) performe

211 nts (hemoglobin A1c=5.4 +/- 0.12) undergoing coronary artery bypass grafting (n=8/group).

212 98), and had no significant effect on adding coronary artery bypass grafting (odds ratio, 0.929; 95%

213 onfidence interval, 1.02-1.19) and emergency coronary artery bypass grafting (odds ratio, 1.32; 95% c

214 n (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior des

215 Off-pump coronary artery bypass grafting (OPCAB) has been suggest

216 n-hospital mortality for patients undergoing coronary artery bypass grafting operations.

217 ose in STICH Hypothesis 2 were randomized to coronary artery bypass grafting or coronary artery bypas

218 d follow-up angiography 12 to 18 months post-coronary artery bypass grafting or earlier clinically dr

219 00 patients >70 years of age to conventional coronary artery bypass grafting or OPCAB surgery.

220 erences in coronary revascularization rates (coronary artery bypass grafting or percutaneous coronary

221 a randomized trial of treatment with either coronary artery bypass grafting or percutaneous coronary

222 the use of routine cardiac stress testing in coronary artery bypass grafting or percutaneous coronary

223 ied, having a primary diagnosis of emergency coronary artery bypass grafting or valve replacement, an

224 of age or older who were planning to undergo coronary-artery bypass grafting or valve replacement.

225 y alone, percutaneous coronary intervention, coronary artery bypass grafting, or more information req

226 ies were used as free grafts or T grafts for coronary artery bypass grafting over a 15-year period.

227 final study cohort included 348 341 isolated coronary artery bypass grafting patients aged >/=65 year

228 In-hospital mortality for coronary artery bypass grafting patients was 8.2%; all-c

229 Survival was significantly higher for coronary artery bypass grafting patients who received in

230 nditions, and in-hospital procedures such as coronary artery bypass grafting, percutaneous coronary i

231 as fatal or nonfatal myocardial infarction, coronary artery bypass grafting, percutaneous translumin

232 definite angina, coronary revascularization (coronary artery bypass grafting, percutaneous translumin

233 Conventional coronary artery bypass grafting performed with the use o

234 ferred 30-day survival benefit among the AVR+coronary artery bypass grafting population (EF>/=50%, 96

235 le-vessel and double-vessel total endoscopic coronary artery bypass grafting procedures have likewise

236 vein harvest in patients undergoing elective coronary artery bypass grafting procedures in Veterans A

237 s coronary intervention procedures and 7,131 coronary artery bypass grafting procedures), 59% had at

238 01 to 2004, 8542 patients underwent isolated coronary artery bypass grafting procedures, 52.5% with e

239 30-day readmissions for patients undergoing coronary artery bypass grafting, pulmonary lobectomy, en

240 We identified patients who underwent coronary artery bypass grafting, pulmonary lobectomy, en

241 readmission rates after hospitalization for coronary-artery bypass grafting, pulmonary lobectomy, en

242 ade: r=0.46; P=0.0001) and SAVR (concomitant coronary artery bypass grafting: r=-0.33; P=0.03).

243 issions Reduction Program formula using only coronary artery bypass grafting readmissions with a 3% m

244 nical role of cardiac troponin testing after coronary artery bypass grafting remain unclear.

245 cal panel felt that based on recent studies, coronary artery bypass grafting remains an appropriate m

246 Coronary artery bypass grafting remains one of the most

247 conduit improves outcomes after multivessel coronary artery bypass grafting remains unclear.

248 , and 33.0% for medical management, PCI, and coronary artery bypass grafting, respectively.

249 Aortic atheroma (TAVI) and concomitant coronary artery bypass grafting (SAVR) are independent r

250 Coronary artery bypass grafting seems to be the preferre

251 trate a survival advantage when treated with coronary artery bypass grafting (severe CAD) or a defibr

252 ion to percutaneous coronary intervention or coronary artery bypass grafting strata reported similar

253 In the coronary artery bypass grafting stratum (n=763), MI even

254 In the coronary artery bypass grafting stratum, 4-year costs we

255 ty of Thoracic Surgeons composite rating for coronary artery bypass grafting (STS-CABG), and Centers

256 Results were similar in the isolated coronary artery bypass grafting subgroup.

257 Coronary artery bypass grafting success is limited by ve

258 ) between CFR and early revascularization by coronary artery bypass grafting, such that patients with

259 retrospective analysis of 47 984 consecutive coronary artery bypass grafting surgeries performed from

260 Among the study population, 1482 coronary artery bypass grafting surgeries with BIMA were

261 Most survival prediction models for coronary artery bypass grafting surgery are limited to i

262 analyzed 20 896 patients undergoing isolated coronary artery bypass grafting surgery at 33 medical ce

263 rs of 30-day all-cause readmission following coronary artery bypass grafting surgery by using nationa

264 icular, the low likelihood of ACEI/ARB after coronary artery bypass grafting surgery or in patients w

265 A coronary artery bypass grafting surgery readmission meas

266 38 patients undergoing nonemergent, isolated coronary artery bypass grafting surgery using cardiopulm

267 l centers among patients undergoing isolated coronary artery bypass grafting surgery.

268 contributor to morbidity and mortality after coronary artery bypass grafting surgery.

269 Following coronary artery bypass grafting, there is a massive incr

270 Rivaroxaban versus placebo increased non-coronary artery bypass grafting Thrombolysis In Myocardi

271 f 283,131 patients who were readmitted after coronary artery bypass grafting, to 142,142 (83.2%) of 1

272 subgroups, including patients who underwent coronary-artery bypass grafting (UHC data: unadjusted od

273 Seventy patients undergoing coronary artery bypass grafting underwent an echocardiog

274 We randomly assigned 304 patients undergoing coronary artery bypass grafting using BITA to either in

275 Patients had a mix of coronary artery bypass grafting, valve surgery, and comb

276 Secondary end points included emergency coronary artery bypass grafting, vascular complications,

277 1); high-performing programs had higher mean coronary artery bypass grafting volumes (n = 241) than a

278 c reporting sites had higher mean annualized coronary artery bypass grafting volumes than nonreportin

279 rtery bypass grafting was 9.5 years and with coronary artery bypass grafting was 5.7 years (P<0.001).

280 Median survival without coronary artery bypass grafting was 9.5 years and with c

281 Survival after AVR or AVR+coronary artery bypass grafting was most favorable among

282 sease, percutaneous coronary intervention or coronary artery bypass grafting was only performed in 69

283 ction (ejection fraction [EF] </=40%) before coronary artery bypass grafting were consecutively enrol

284 , patient-level mortality rates for isolated coronary artery bypass grafting were consistently lower

285 reating 361 328 patients undergoing isolated coronary artery bypass grafting were randomized to eithe

286 esis 1 were randomized to medical therapy or coronary artery bypass grafting, whereas those in STICH

287 age undergoing primary isolated nonemergent coronary artery bypass grafting with 3-vessel disease we

288 nts with postoperative catheterization after coronary artery bypass grafting with a radial artery gra

289 ndomized clinical trial, patients undergoing coronary artery bypass grafting with an internal mammary

290 o 40% and scheduled for isolated or combined coronary artery bypass grafting with cardiopulmonary byp

291 th low ejection fraction who were undergoing coronary artery bypass grafting with cardiopulmonary byp

292 1107 consecutive diabetic patients underwent coronary artery bypass grafting with either SIMA (n=646)

293 omized to coronary artery bypass grafting or coronary artery bypass grafting with left ventricular re

294 who underwent primary, isolated multivessel coronary artery bypass grafting with the left internal t

295 studies comparing the long-term outcomes of coronary artery bypass grafting with the use of 2-arteri

296 tus by percutaneous coronary intervention or coronary artery bypass grafting within 7 days of the ind

297 ation (percutaneous coronary intervention or coronary artery bypass grafting) within 4 years of the i

298 ent angiography or revascularization (PCI or coronary artery bypass grafting) within 90 days.

299 with multivessel disease who are undergoing coronary artery bypass grafting without increased mortal

300 echocardiography), coronary angiography, or coronary artery bypass grafting (without angiography) as